Federated Hermes
LBRX

Federated Hermes’s LB Pharmaceuticals LBRX Stock Holding History

Federated Hermes’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.1K Sell
2,500
-2,500
-50% -$73.4K ﹤0.01% 1643
2026
Q1 		$123K Hold
5,000
– – ﹤0.01% 1560
2025
Q4 		$111K Sell
5,000
-4,000
-44% -$69.9K ﹤0.01% 1568
2025
Q3 		$142K Buy
+9,000
New +$143K ﹤0.01% 1541

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Federated Hermes's LBRX Position: Q2 2026 in Review

Federated Hermes reduced its LB Pharmaceuticals (LBRX) stake by 50% in Q2 2026, selling an estimated $73.4K and leaving 2,500 shares worth $81.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

Federated Hermes first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $142K in Q3 2025. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Federated Hermes held 2,500 shares of LB Pharmaceuticals worth $81.1K as of Q2 2026.
  • Federated Hermes sold 2,500 LB Pharmaceuticals shares in Q2 2026, an estimated $73.4K.
  • LB Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1643 holding.
  • Federated Hermes first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Federated Hermes's LB Pharmaceuticals position peaked at $142K in Q3 2025.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.